Swiss pharmaceutical giant Roche has announced its plan to acquire U.S. biopharmaceutical company Poseida Therapeutics for up to $1.5 billion. Roche has entered into a definitive merger agreement to purchase Poseida at $9 per share, valuing Poseida's total equity at approximately $1 billion.
The deal includes provisions that allow Poseida shareholders to receive an additional $4 per share in cash, contingent on future performance metrics. This could bring the total transaction value to around $1.5 billion. Roche anticipates completing the acquisition by the first quarter of 2025.
The acquisition will include Poseida Therapeutics' cell therapy candidates and associated platform technologies. Poseida is a publicly traded, clinical-stage biopharmaceutical company focused on developing donor-derived CAR-T cell therapies. These therapies are customized for individual patients by collecting and re-engineering their T-cells (a type of white blood cell) in a laboratory setting.
Roche highlighted that the therapies under development cover multiple treatment areas, including hematologic malignancies, solid tumors, and autoimmune diseases, alongside manufacturing capabilities and technology platforms.
